BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 [PMID: 34621472 DOI: 10.4240/wjgs.v13.i9.953]
URL: https://www.wjgnet.com/1948-5182/full/v13/i9/953.htm
Number Citing Articles
1
Reimi Suzuki, Ryoichi Goto, Norio Kawamura, Masaaki Watanabe, Yoshikazu Ganchiku, Kanako C Hatanaka, Yutaka Hatanaka, Toshiya Kamiyama, Tsuyoshi Shimamura, Akinobu Taketomi. Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantationClinical Journal of Gastroenterology 2022; 15(4): 755 doi: 10.1007/s12328-022-01643-3
2
Roberto Gambari, Cristina Zuccato, Lucia Carmela Cosenza, Matteo Zurlo, Jessica Gasparello, Alessia Finotti, Maria Rita Gamberini, Marco Prosdocimi. The Long Scientific Journey of Sirolimus (Rapamycin): From the Soil of Easter Island (Rapa Nui) to Applied Research and Clinical Trials on β-Thalassemia and Other HemoglobinopathiesBiology 2023; 12(9): 1202 doi: 10.3390/biology12091202
3
Faiza Ahmed, Faiza Zakaria, Godsgift Enebong Nya, Mohamad Mouchli. Sirolimus <i>vs</i> tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma?World Journal of Gastrointestinal Surgery 2022; 14(8): 862-866 doi: 10.4240/wjgs.v14.i8.862